Sarah Whitley is a Dermatology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
281 Lincoln St
Worcester, MA 016052138
Telephone
508-334-5979Provider last certified this registry record 15 Sept 2022.
Clinical trials
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa
Sponsor: University of Massachusetts, Worcester
- Botulinum Toxin Therapy in Hidradenitis Suppurativa
Sponsor: University of Massachusetts, Worcester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB SAProgram year20251 payment
- ABBVIE INC.Program year20254 payments
- UCB, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
42.5%TNF inhibitor42.5%Remicade100%Part D<11 patientsDermatology
30%Corticosteroid30%Triamcinolone Acetonide100%Part D<11 patientsAnti-infectives
27.5%Lincosamide Antibacterial27.5%Clindamycin Phosphate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Targeting cutaneous nociceptors to reduce Type-17 inflammation in hidradenitis suppurativa
Univ of Massachusetts Med Sch Worcester
FY2026$168,458K08AR080844 - Targeting cutaneous nociceptors to reduce Type-17 inflammation in hidradenitis suppurativa
Univ of Massachusetts Med Sch Worcester
FY2025$168,458K08AR080844 - Targeting cutaneous nociceptors to reduce Type-17 inflammation in hidradenitis suppurativa
Univ of Massachusetts Med Sch Worcester
FY2024$168,458K08AR080844
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”